Edition:
United States

Vascular Biogenics Ltd (VBLT.OQ)

VBLT.OQ on NASDAQ Stock Exchange Global Market

1.18USD
3:59pm EST
Change (% chg)

$0.02 (+1.72%)
Prev Close
$1.16
Open
$1.25
Day's High
$1.25
Day's Low
$1.15
Volume
82,803
Avg. Vol
19,500
52-wk High
$8.75
52-wk Low
$1.09

Latest Key Developments (Source: Significant Developments)

Vascular Biogenics Q3 Loss Per Share $0.15
Tuesday, 20 Nov 2018 07:02am EST 

Vascular Biogenics Ltd ::VBL THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.15.VASCULAR BIOGENICS - ESTIMATES CURRENT CASH, OTHERS TO BE SUFFICIENT TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS FOR OVER 3 YEARS.  Full Article

Vbl Therapeutics Announces Q1 Loss Per Share $0.24
Thursday, 17 May 2018 07:00am EDT 

May 17 (Reuters) - Vascular Biogenics Ltd ::VBL THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.24.SAYS CASH, CASH EQUIVALENTS AND SHORT-TERM BANK DEPOSITS AT MARCH 31, 2018, WERE $49.9 MILLION.  Full Article

Vascular Biogenics Says Top-Line Data From Globe Phase 3 Pivotal Trial Of VB-111 Expected In Q1 Of 2018
Wednesday, 27 Dec 2017 07:00am EST 

Dec 27 (Reuters) - Vascular Biogenics Ltd ::VASCULAR BIOGENICS - TOP-LINE DATA FROM GLOBE PHASE 3 PIVOTAL TRIAL OF VB-111 EXPECTED IN Q1 OF 2018.  Full Article

VBL therapeutics Q3 loss per share $0.24
Tuesday, 14 Nov 2017 07:00am EST 

Nov 14 (Reuters) - Vascular Biogenics Ltd :VBL Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.24.Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Vascular Biogenics Ltd - ‍ remain on-track to initiate a phase 3 study of vb-111 in ovarian cancer by year-end 2017​.Vascular Biogenics Ltd - ‍ also planning an exploratory clinical study in combination with a checkpoint inhibitor in lung cancer in q1 of 2018​.Vascular Biogenics - ‍expect cash, cash equivalents, short-term bank deposits to enable funding operating expenses and capex requirements through 2019​.  Full Article

VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Nanocarrier Co Ltd <4571.T>:VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan.Vascular Biogenics Ltd - ‍Nanocarrier receives exclusive rights to VB-111 in Japan, VBLT retains rights in rest of world​.Vascular - Pursuant to agreement, VBLT to supply nanocarrier with VB-111.Vascular - Nanocarrier will be responsible for all regulatory, other clinical activities necessary for commercialization of VB-111 in Japan.Vascular - VBLT receives up-front payment of $15 million & is entitled to receive greater than $100 million in development & commercial milestone payments​.Vascular Biogenics Ltd - ‍VBLT will also receive tiered royalties on net sales in high-teens​.Vascular Biogenics Ltd - ‍Other terms of agreement not disclosed​.  Full Article

Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan
Sunday, 5 Nov 2017 09:40pm EST 

Nov 6 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says co signs an exclusive license agreement with VBL Therapeutics, for the development, commercialization, and supply of ofranergene obadenovec ("VB-111") in Japan.Under terms of the agreement, VBL Therapeutics will supply the co with VB-111, and the co will be responsible for all regulatory and other clinical activities necessary for commercialization in Japan.Says VBL Therapeutics will receive up-front payment of $15 million, development and commercial milestone payments and tiered royalties on net sales from the co.  Full Article

VBL THERAPEUTICS OPENS NEW GENE THERAPY MANUFACTURING PLANT, HEADQUARTERS
Monday, 23 Oct 2017 08:05am EDT 

Oct 23 (Reuters) - Vascular Biogenics Ltd ::VBL THERAPEUTICS CELEBRATES OPENING OF ITS NEW GENE THERAPY MANUFACTURING PLANT AND COMPANY HEADQUARTERS.PLANT IN MODIIN, ISRAEL WILL BE COMMERCIAL FACILITY FOR PRODUCTION OF OFRANERGENE OBADENOVEC (VB-111), IF APPROVED​.‍VBL EXPECTS THAT CURRENT CASH WILL FUND COMPANY'S OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO 2019​.  Full Article

VBL Therapeutics says VB-111 given orphan drug designation in Europe
Friday, 20 Oct 2017 07:00am EDT 

Oct 20 (Reuters) - Vascular Biogenics Ltd :VBL Therapeutics announces orphan drug designation for VB-111 in Europe.VBL Therapeutics - ‍European Medicines Agency designated ofranergene obadenovec as an "orphan medicinal product" for treatment of ovarian cancer​.  Full Article